Personalis Stock Price, News & Analysis

Personalis, a leader in advanced cancer genomics, will participate in the Society for Immunotherapy of Cancer Annual Meeting from November 12-14. The company will present online exhibits, including the Personalis NeXT Platform for comprehensive tumor and immune microenvironment analysis. Key presentations include research on liquid biopsies and therapeutic resistance in various cancers. An industry symposium titled 'Leveraging comprehensive genomic data for diagnostic capabilities' will also be featured on November 12.

Personalis, Inc. (Nasdaq: PSNL) reported a 12% increase in third-quarter revenue, totaling $22.3 million compared to $19.8 million in 2020. The company achieved record revenue of $8.6 million from biopharma clients, a 50% growth. New orders for cancer genomic testing exceeded quarterly revenue by three times. Notably, Personalis secured a $10 million contract with the VA Million Veteran Program. Despite these gains, the net loss rose to $17.7 million, worsening from a $9.5 million loss in the previous year. The fourth quarter outlook anticipates revenue between $20.2 million and $20.4 million.

Personalis, Inc. (NASDAQ: PSNL) has expanded its NeXT Platform, enhancing its ability to analyze tumor-immune interactions crucial for cancer therapy responses. Key new features include InfiltrateID™, which identifies immune cell populations; RepertoireID™, which characterizes B-cell receptors; and SHERPA™, an advanced neoantigen prediction algorithm. These improvements aim to facilitate better patient stratification in cancer treatments. Personalis continues to be a leader in advanced genomics, operating a significant sequencing operation and focusing on comprehensive genomic tumor profiling.

Personalis, Inc. (NASDAQ: PSNL) announced the issuance of two significant US patents on October 12 and 26, 2021, related to its NeXT Liquid Biopsy platform. The first patent, US Patent No. 11,142,802, focuses on methods for identifying cancer mutations in cell-free nucleic acids, especially beneficial for early-stage cancer patients. The second patent, US Patent No. 11,155,867, details a deep sequencing method for analyzing exomes from cell-free samples. Combined, these patents enhance Personalis' intellectual property portfolio, supporting advancements in cancer detection and treatment.

Personalis, Inc. (Nasdaq: PSNL) announced the publication of its study on the SHERPA™ algorithm, significantly improving MHC-peptide binding prediction for neoantigen discovery. This new machine learning tool demonstrates a 1.44-fold increase in positive predictive value over existing tools, trained on a dataset of 2.15 million peptides across 167 HLA alleles. The study emphasizes SHERPA's potential in enhancing cancer therapy prediction and accelerating the development of personalized treatments, leveraging data from diverse cell lines.

Personalis, Inc. (NASDAQ: PSNL) will announce its third quarter 2021 financial results on November 4, 2021, before the market opens. The company will host a conference call at 5:30 a.m. PT to discuss its financials and recent developments. Interested parties can join via telephone or access a live webinar through the company’s investor website. Personalis specializes in advanced cancer genomics, providing insights from approximately 20,000 human genes, which facilitates precision cancer therapies and diagnostics.

Personalis, Inc. (NASDAQ: PSNL) has appointed Robert Bruce as Vice President of Reimbursement. With over 25 years of experience in reimbursement strategies within clinical molecular diagnostics, Bruce aims to enhance access to advanced molecular diagnostic tests for cancer. Prior to joining Personalis, he held leadership roles at Clinical Genomics and other companies. His expertise is expected to facilitate growth in clinical laboratory testing at Personalis, enabling innovative solutions for understanding cancer at a molecular level.

Mayo Clinic has partnered with Personalis Inc. (Nasdaq: PSNL) to offer clinical-grade comprehensive cancer genomic sequencing. Announced on October 12, the collaboration aims to provide genomic testing for cancer patients, guiding treatment decisions and advancing research. The test will analyze the entire coding genome, with results available to both patients and their healthcare providers. Mayo Clinic officials emphasize the importance of diverse patient access to such advanced testing, which seeks to improve treatment personalization and contribute data to develop new therapies.